Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2014
Reply to C. Fontanella et al
Hatem A Azim, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
Journal of Clinical Immunology
|
November 23, 2018
Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
Rajiv Mallick, Stephen Jolles, Hirokazu Kanegane, et al.
International Journal of Cancer
|
November 5, 2020
STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial
Amir Sonnenblick, Dominique Agbor-Tarh, Evandro de Azambuja, et al.
Breast Cancer Research : BCR
|
October 28, 2020
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Serena Di Cosimo, Luca Porcu, Dominique Agbor-Tarh, et al.
Breast Cancer Research and Treatment
|
September 20, 2020
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)
Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, et al.
Breast Cancer Research and Treatment
|
October 9, 2021
Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D)
Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 5, 2021
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial
Samuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, et al.
ESMO Open
|
November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
Matteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
British Journal of Cancer
|
March 24, 2020
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
Daniel Eiger, Noam F Pondé, Dominique Agbor-Tarh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 20, 2013
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial
Hatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2014
Reply to C. Fontanella et al
Hatem A Azim, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
Journal of Clinical Immunology
|
November 23, 2018
Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
Rajiv Mallick, Stephen Jolles, Hirokazu Kanegane, et al.
International Journal of Cancer
|
November 5, 2020
STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial
Amir Sonnenblick, Dominique Agbor-Tarh, Evandro de Azambuja, et al.
Breast Cancer Research : BCR
|
October 28, 2020
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Serena Di Cosimo, Luca Porcu, Dominique Agbor-Tarh, et al.
Breast Cancer Research and Treatment
|
September 20, 2020
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)
Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, et al.
Breast Cancer Research and Treatment
|
October 9, 2021
Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D)
Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 5, 2021
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial
Samuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, et al.
ESMO Open
|
November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
Matteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
British Journal of Cancer
|
March 24, 2020
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
Daniel Eiger, Noam F Pondé, Dominique Agbor-Tarh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 20, 2013
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial
Hatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.
Page
of 2